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MaOBJECTIVES This study sought to investigate whether the beneﬁcial impact of high-dose rosuvastatin against
contrast-induced acute kidney injury (CI-AKI) in acute coronary syndrome (ACS) patients varied in relation to baseline
high-sensitivity C-reactive protein (hs-CRP) levels.
BACKGROUND High-dose rosuvastatin administered on admission has been shown to prevent CI-AKI and improve
short- and mid-term clinical outcome in ACS patients.
METHODS All 504 statin-naïve ACS patients enrolled in the PRATO-ACS (Protective Effect of Rosuvastatin and Anti-
platelet Therapy on Contrast-Induced Acute Kidney Injury and Myocardial Damage in ACS Patients) study were stratiﬁed
into baseline hs-CRP tertiles: <2.7 mg/l, $2.7 to <7.5 mg/l, and $7.5 mg/l. The primary endpoint was CI-AKI occurrence
(creatinine $0.5 mg/dl or $25% above baseline within 72 h). Logistic regression models were used to evaluate the
relationship between hs-CRP levels and effects of rosuvastatin.
RESULTS Patients with higher baseline hs-CRP values presented a signiﬁcantly higher incidence of CI-AKI (5.4%, 8.7%,
and 18.3% in the ﬁrst, second, and third tertiles, respectively; p ¼ 0.0001). The beneﬁcial effect of rosuvastatin was
markedly signiﬁcant in the third hs-CRP tertile (odds ratio: 0.20; 95% conﬁdence interval: 0.07 to 0.54; p ¼ 0.002).
Statin-treated patients in the third tertile presented a signiﬁcantly lower rate of adverse events at 30 days (7.2% vs.
17.4%, p ¼ 0.043) with a trend toward better outcome at 6 months (6.02% vs. 13.04%, p ¼ 0.12).
CONCLUSIONS High-dose rosuvastatin administered on admission appears to exert more effective kidney protection in
ACS subjects with higher baseline hs-CRP levels resulting in better short- and mid-term clinical outcome. (Protective
Effect of Rosuvastatin and Antiplatelet Therapy on Contrast-Induced Nephropathy and Myocardial Damage in Patients
With Acute Coronary Syndrome Undergoing Coronary Intervention [PRATO-ACS]; NCT01185938) (J Am Coll Cardiol Intv
2014;7:1421–9) © 2014 by the American College of Cardiology Foundation.m the *Cardiology Division, Prato Hospital, Prato, Italy; and the ySection of Biostatistics and Clinical Epidemiology, Depart-
nt of Public Health, Neurosciences, Experimental, and Forensic Medicine, Pavia University, Pavia, Italy. The study was
pported by the Centro Cardiopatici Toscani. All authors have reported that they have no relationships relevant to the
tents of this paper to disclose.
nuscript received March 14, 2014; revised manuscript received June 3, 2014, accepted June 18, 2014.
TABLE 1 Baseline Clinical, Biochemical, and Angiographic
Characteristics
Statin
(n ¼ 252)
Control
(n ¼ 252) p Value*
Age, yrs 66.2  12.4 66.1  13.5 0.91
Age $70 yrs 117 (46.4) 113 (44.8) 0.72
Male 166 (65.9) 165 (65.5) 0.93
BMI, kg/m2 26.2  3.7 26.6  4.4 0.35†
Risk factors
Hypertension 143 (56.7) 138 (54.8) 0.65
Diabetes mellitus 50 (19.8) 57 (22.6) 0.45
Active smoking 89 (35.3) 81 (32.1) 0.45
Total cholesterol
>200 mg/dl
116 (46) 130 (51.6) 0.21
eCrCl, ml/min 69.9  24.4 69.3  24.9 0.81
eGFR, ml/min/m2 82.5  2 82.6  22 0.96
Previous MI 24 (9.5) 15 (5.9) 0.13
ABBR EV I A T I ON S
AND ACRONYMS
ACS = acute coronary
syndrome
CI = conﬁdence interval
CI-AKI = contrast-induced
acute kidney injury
CRP = C-reactive protein
hs-CRP = high-sensitivity
C-reactive protein
NSTE = non–ST-segment
elevation
OR = odds ratio
ORadj = adjusted odds ratio
PCI = percutaneous
coronary intervention
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1422I ncreased systemic inﬂammation evi-denced by elevated C-reactive protein(CRP) levels is associated with higher
risk of cardiovascular events (1–3). There is
a growing body of evidence that the beneﬁt
of statin therapy may also be related to
the drug anti-inﬂammatory effects (4–6). Pa-
tients with higher CRP levels treated with sta-
tins show substantially greater reduction of
cardiovascular events than those without
signs of inﬂammation, even in cases of low-
density lipoprotein cholesterol levels (6).
Elevated CRP levels are also associated
with endothelial injury and impaired vaso-
dilation, which may lead to acute renal
damage and progressive loss of kidney func-Previous PCI or CABG 30 (11.9) 18 (7.1) 0.07
Baseline LVEF, % 50  9 50  9 >0.90
High-risk clinical features 180 (71.4) 169 (67.1) 0.29
Laboratory variables
at baseline
hs-CRP, mg/l 4.2 (2.2–10.5) 4.6 (2.0–10.2) 0.55
Leukocytes, 103/ml 7.9 (6.5–10) 8.4 (6.7–10.1) 0.3
Neutrophils, 103/ml 4.9 (3.7–6.9) 5.1 (4–6.9) 0.29
Monocytes, 103/ml 0.6 (0.5–0.8) 0.6 (0.5–0.8) 0.57
Lymphocytes, 103/ml 2 (1.5–2.4) 1.9 (1.5–2.4) 0.42
Glycemia, mg/dl 117 (102–144) 120 (104–147) 0.31
Serum creatinine, mg/dl 0.95  0.27 0.96  0.28 0.89
Hemoglobin, mg/dl 14.1  1.6 14.1  1.6 0.77
cTn-I, ng/ml 0.51 (0.08–1.9) 0.6 (0.09–2.32) 0.41
CK-MB, ng/ml 6.3 (3–18.3) 6.9 (3.1–20.3) 0.34
LDL cholesterol, mg/dl 135.2  38.6 135.8  42.7 0.85
HDL cholesterol, mg/dl 40.2  13.7 42.3  13.3 0.08
Triglycerides, mg/dl 119.7  62.8 118  73 0.78
Angiographic data
Multivessel disease 123 (48.8) 120 (47.6) 0.78
CI-AKI risk score 3 (1, 6) 2 (1, 5) 0.36‡
PCI revascularization 171 (67.9) 162 (64.3) 0.39
Time intervals, h
Symptom onset to
randomization
10 (6–20) 11.5 (6–24) 0.11‡
Randomization to
angiography
22.5 (14–43) 23 (15–45.5) 0.79‡
Hospital stay, days 5 (4–7) 5 (4–7) 0.79
Values are mean  SD, n (%), or median (interquartile range). Quantitative vari-
ables were assessed by the following: *parametric unpaired Student t test;
†parametric unpaired Student t test with Satterthwaite correction for degrees of
freedom; or the ‡analogous nonparametric Wilcoxon-Mann-Whitney test. Chi-
squared or Fischer exact test was used for categorical variables.
BMI ¼ body mass index; CABG ¼ coronary artery bypass graft; CI-AKI ¼
contrast-induced acute kidney injury; CK-MB ¼ creatine kinase-myocardial band;
cTnI ¼ cardiac troponin I; eCrCl ¼ estimated creatinine clearance; eGFR ¼
estimated glomerular ﬁltration rate; HDL ¼ high-density lipoprotein; hs-CRP ¼
high-sensitivity C-reactive protein; LDL ¼ low-density lipoprotein; LVEF ¼ left
ventricular ejection fraction; MI ¼ myocardial infarction; PCI ¼ percutaneous
coronary intervention.tion (7). Systemic inﬂammation could render the
kidneys more vulnerable to local inﬂammatory pro-
cesses elicited by iodinated contrast medium reab-
sorption following angiographic procedures, favoring
development of contrast-induced acute kidney injury
(CI-AKI) (8–10). Recent randomized studies have
evidenced the beneﬁcial effects of statins against CI-
AKI especially in high-risk patients such as those
with diabetes or acute coronary syndrome (ACS) who
present evident signs of inﬂammation (10–16).
The continued evidence of the beneﬁcial effects of
statins in these patients and the presumed impor-
tance of inﬂammation in the pathogenesis of acute
renal damage encouraged us to focus on the possible
speciﬁc relationship between statin treatment and
baseline CRP levels in our PRATO-ACS (Protective
Effect of Rosuvastatin and Antiplatelet Therapy on
Contrast-Induced Acute Kidney Injury and Myocar-
dial Damage in ACS Patients) study patients. The
PRATO-ACS randomized study has shown that in
addition to standard preventive measures (intrave-
nous hydration, use of low- or iso-osmolar contrast
media and reduced dosages of contrast agents) early
high-dose rosuvastatin administration reduces CI-AKI
occurrence and improves short- and mid-term clinical
outcome in statin-naïve patients with ACS without
ST-segment elevation (NSTE) selected for early inva-
sive strategy (15).
METHODS
The design and main results of the PRATO-ACS
study have been previously described (15). Brieﬂy,
543 statin-naïve patients with NSTE-ACS scheduled
for early invasive strategy were enrolled in the trial
immediately on admission. Exclusion criteria were
as follows: long-term lipid-lowering therapy at the
time of the index ACS; high-risk features warrantingemergency coronary angiography (within 2 h); acute
renal failure or end-stage renal failure requiring
dialysis or serum creatinine $3 mg/dl; severe
comorbidities that precluded early invasive strategy;
TABLE 2 Cumulative Incidence of Primary and Additional Endpoints by Treatment Group
Statin Group Control Group
Crude OR
(95% CI) p Value
Adjusted OR*
(95% CI) p Value
Primary CI-AKI criteria
Serum creatinine increase $0.5 mg/dl or
25% over baseline within 72 h
17 (6.7) 38 (15.1) 0.41 (0.22–0.74) 0.003 0.41 (0.22–0.77) 0.005
Additional different CI-AKI criteria
Creatinine $0.5 mg/dl or
25% within 48 h
16 (6.3) 30 (11.9) 0.50 (0.27–0.95) 0.033 0.50 (0.26–0.97) 0.039
Creatinine $0.3 mg/dl within 48 h 9 (3.6) 22 (8.7) 0.39 (0.17–0.86) 0.02 0.37 (0.15–0.89) 0.026
Creatinine $0.3 mg/dl within 72 h 11 (4.4) 27 (10.7) 0.38 (0.18–0.78) 0.009 0.38 (0.17–0.82) 0.014
Creatinine $0.5 mg/dl within 72 h 6 (2.4) 15 (5.9) 0.38 (0.15–1.01) 0.052 0.45 (0.16–1.29) 0.137
Estimated GFR #25% within 72 h 14 (5.6) 29 (11.5) 0.45 (0.24–0.86) 0.015 0.47 (0.24–0.92) 0.028
Values are n (%) unless otherwise indicated. Unconditional logistic model was applied and crude and adjusted odds ratio with 95% conﬁdence intervals are reported. *Adjusted
ORs were controlled for hs-CRP (continuous variable), sex, age, diabetes, hypertension, LDL-cholesterol values, creatinine clearance at baseline, ejection fraction, contrast ratio,
and CI-AKI risk score.
CI ¼ conﬁdence interval; GFR ¼ glomerular ﬁltration rate; OR ¼ odds ratio; other abbreviations as in Table 1.
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1423contraindications to statin treatment; contrast media
administration within the last 10 days; pregnancy; or
refusal of consent. Eligible patients were randomly
assigned to receive high-dose rosuvastatin (statin
group) or no statin treatment (control group). After
randomization, 39 patients were excluded from the
ﬁnal analysis for the following reasons: 17 had not
undergone angiography, and 22 did not complete
creatinine determination. Thus, a total of 504 pa-
tients were analyzed, 252 per group.
At the time of randomization, patients in the
statin group were administered 40 mg of rosuvastatin
followed by 20 mg/day (time of statin administra-
tion: 10 PM); the control group did not receive
statin treatment. At discharge, statin group patients
continued treatment with 20 mg/day rosuvastatin
(10 mg/day for patients with estimated glomerular
ﬁltration rate <30 ml/min/m2) whereas control
subjects received 40 mg/day atorvastatin.
Serum creatinine was measured at baseline (always
before hydration) and at 24, 48, and 72 h after
contrast media administration; a further measure-
ment was performed at 30 days in all CI-AKI cases.
High-sensitivity C-reactive protein (hs-CRP) was
measured on admission (always before randomiza-
tion) with an immunoturbodimetric assay (Unicel DxC
Clinical Systems 800, Beckman Coulter Inc., Brea,
California); the working range of the assay was 0.0 to
5.0 mg/l. Total and differential white blood cell
counts were obtained with a Coulter LH 750 Analyzer
(Beckman Coulter Inc., Brea, California). All tests,
even after discharge, were done in our hospital lab-
oratory with consistent methodology.
The primary endpoint of the PRATO-ACS study was
CI-AKI deﬁned as an increase in serum creatinine
of $0.5 mg/dl or $25% over the baseline value within72 h after contrast agent administration. Additional
endpoints were as follows: CI-AKI deﬁned by other
criteria; CI-AKI occurrence in pre-speciﬁed risk sub-
groups; adverse cardiovascular and renal events at
30 days including acute renal failure requiring dialysis,
persistent renal damage, all-cause mortality, myo-
cardial infarction, or stroke; and all-cause mortality or
nonfatal myocardial infarction rate at 6 months (15).
The protocol was approved by the hospital ethics
committee and all patients gave written informed
consent.
STATISTICAL ANALYSIS. Categorical variables were
summarized as percentages and continuous variables
as mean  SD or median with interquartile range. The
differences between categorical variables were in-
vestigated by chi-squared or Fisher exact tests. Para-
metric unpaired Student t test (with Satterthwaite
correction for degrees of freedom when necessary) or
the analogous nonparametric test (Wilcoxon-Mann-
Whitney test ¼ U) was applied to evaluate differences
for continuous variables between the statin and the
control groups.
Spearman correlation coefﬁcient was used to mea-
sure the relationship between hs-CRP and various
clinical and laboratory variables.
Patients were stratiﬁed into 3 groups according
to tertiles of baseline hs-CRP: <2.7 mg/l; $2.7 to
<7.5 mg/l; and $7.5 mg/l. Baseline characteristics of
the 3 groups were compared using chi-square analysis
for categorical variables and parametric or nonpara-
metric analysis of variance (Kruskal-Wallis test) for
continuous variables. Multiplicity issues resulting
from the pairwise comparisons with respect to the
highest tertile ($7.5 mg/l) were solved applying
the Bonferroni corrections (yielding a signiﬁcance
threshold of 0.025).
TABLE 3 Baseline Characteristics by Baseline hs-CRP Tertiles
hs-CRP
1st Tertile
(#0.27 mg/dl)
2nd Tertile
(>0.27– #0.75 mg/dl)
3rd Tertile
(>0.75 mg/dl) p Value‡
Age (yrs)* 64.0  13.0† 64.0  13.0† 70.1  12.0 <0.0001
Age $ 70 yrs 61 (36.3)† 67 (41.6)† 102 (58.3) <0.0001
Male 113 (67) 111 (69) 107 (62) 0.28
BMI (kg/m2)* 26  4† 26  4† 27  5 0.005§
Risk factors
Hypertension 86 (51)† 82 (51)† 113 (65) 0.01
Diabetes mellitus* 31 (18.5)† 27 (17)† 49 (28) 0.024
Active smoking 52 (31.0) 63 (39.0) 55 (31.4) 0.21
Total cholesterol >200 mg/dl 88 (52.4) 88 (54.7)† 71 (40.6) 0.02
eCrCl (ml/min) 75.3  22.0† 72.3  26.0† 62.0  24.0 <0.0001
Previous MI 12 (7.0) 10 (6.2) 17 (9.7) 0.465
Previous PCI or CABG 18 (10.7) 12 (7.5) 18 (10.3) 0.55
Previous stroke* 7 (4.2) 2 (1.2)† 14 (8) 0.012
Baseline LVEF (%)* 52  8† 51  8† 47  10 0.0001§
High-risk clinical features* 103 (61) 105 (65) 141 (81) 0.0001
Laboratory variables at baseline
Leucocytes* 7.2 (6.2–8.9)† 7.6 (6.6–9.8)† 9.3 (7.8–11.7) 0.0001§
Neutrophils* 4.3 (3.6–5.9)† 4.6 (3.6–6.2)† 6.2 (4.9–8.5) 0.0001§
Monocytes* 0.5 (0.5–0.7)† 0.6 (0.5–0.8)† 0.75 (0.6–1.0) 0.0002§
Lymphocytes 2.03  0.7 2.1  0.8† 1.9  0.7 0.053
Hemoglobin (mg/dl)* 14.3  1.3† 14.2  1.6† 13.7  1.8 0.0001
cTn-I (ng/ml)* 0.19 (0.04–0.9)† 0.51 (0.11–1.8)† 1.4 (0.2–5.04) 0.0001§
CK-MB (ng/ml)* 4.5 (2.5–12.1)† 6.9 (3.2–19.7)† 9.8 (3.6–23.2) 0.0001§
LDL-cholesterol (mg/dl) 139  38† 141  40† 127  43 0.006
HDL-cholesterol (mg/dl) 43  11† 41  13 39  14 0.03
Triglycerides (mg/dl) 112.4  63 122  72 122  68 0.23
Glycemia (mg/dl)* 110 (97–134)† 115 (102–137)† 129 (109–178) 0.0001§
Time intervals
Symptom-to-randomization (hrs)* 9 (5–18)† 11 (6–19) 12 (6–24) 0.0018§
Randomization-to-angiography (hrs) 21 (12.5–40.0)† 23 (16–43) 26 (15–55) 0.02§
Hospital stay (days) 5 (4–6)† 5 (4–6)† 6 (4–8) 0.0001§
Angiographic data and treatment
Multivessel disease* 71 (50)† 71 (51)† 101 (70) 0.001
Contrast volume (ml) 147  80 142  75 143  90 0.59§
Contrast volume >140 (ml) 79 (47) 66 (41) 73 (42) 0.48
No-PCI 51 (30) 51 (32) 69 (39) 0.45
PCI 117 (70) 110 (68) 106 (61)
CI-AKI risk score* 2 (1–5)† 2 (1–5)† 4 (1–7) 0.0001§
Values are mean  SD, n (%), or median (interquartile range). *Parameters signiﬁcantly correlated with baseline hs-CRP (p < 0.05). †Signiﬁcant pairwise comparison with 3rd
hs-CRP tertile (p < 0.025). ‡Chi-squared or Fisher exact test was used for categorical variables. §Parametric or nonparametric analysis of variance was applied to quantitative
variables.
Abbreviations as in Table 1.
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1424Rates of CI-AKI were compared between tertiles
using chi-square analysis. The multivariate logistic
analysis performed to evaluate the association be-
tween statin treatment and CI-AKI occurrence
included various potential prognostic and confound-
ing factors such as sex, age, diabetes, hypertension,
low-density lipoprotein cholesterol level, creatinine
clearance at baseline, left ventricular ejection frac-
tion, contrast volume, CI-AKI risk score, and baseline
hs-CRP. Baseline hs-CRP was entered into the modelsas either a continuous or categorical variable, using
the 3 tertiles described. The association between
treatment and CI-AKI was expressed as odds ratio
(OR) and 95% conﬁdence interval (CI).
An interaction term for statin treatment and base-
line hs-CRP levels was also introduced into the
multivariate models to examine the possible role as
effect modiﬁer. All probability values were 2-tailed
and a p value of <0.05 was considered signiﬁcant.
All the analyses were carried out using STATA
20
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1425software (version 12, StataCorp LP, College Station,
Texas).10
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FIGURE 1 CI-AKI Rates by Baseline hs-CRP Tertiles
Incidence of contrast-induced acute kidney injury (CI-AKI) in patients divided into tertiles
of baseline high-sensitivity C-reactive protein (hs-CRP): (A) overall population (504
patients); (B) patients divided into statin and control groups.
FIGURE 2 Baseline hs-CRP Tertiles and Risk of CI-AKI
The association between statin treatment and CI-AKI occurrence in the overall population
(n ¼ 504) and in patients stratiﬁed into tertiles of baseline hs-CRP levels. Odds ratios are
adjusted (adj) for sex, age, diabetes, hypertension, low-density lipoprotein cholesterol
level, creatinine clearance at baseline, left ventricular ejection fraction, contrast volume,
CI-AKI risk score, and baseline hs-CRP (categorical variable). CI ¼ conﬁdence interval;
other abbreviations as in Figure 1.RESULTS
Table 1 shows baseline clinical, biochemical, and
angiographic parameters in the statin and control
groups. There were no signiﬁcant differences be-
tween the 2 groups regarding baseline hs-CRP values
and other clinical and biochemical inﬂammation-
related factors, including, for example, body mass
index, glycemia, hemoglobin, creatinine clearance,
leukocytes. Other parameters investigated are re-
ported in a previous paper (15).
Overall, 55 patients (10.9%) developed CI-AKI after
angiographic procedure: 17 (6.7%) in the statin group
and 38 (15.1%) in the control group with a crude odds
ratio of 0.41 (95% CI: 0.22 to 0.74; p ¼ 0.003) (15).
Adjusting the original logistic model for baseline hs-
CRP (continuous variable), this OR remains highly
signiﬁcant (adjusted odds ratio [ORadj]: 0.41, 95% CI:
0.22 to 0.77; p ¼ 0.005), showing that rosuvastatin
pre-treatment exerted a signiﬁcant protective effect
against CI-AKI occurrence independent of baseline
hs-CRP. This favorable effect was consistently con-
ﬁrmed even using nonprimary endpoint CI-AKI
criteria (Table 2). No signiﬁcant statistical interac-
tion between treatment allocation and baseline levels
of hs-CRP was observed (p ¼ 0.25).
EFFECT OF STATIN PRE-TREATMENT ON CI-AKI BY
BASELINE HS-CRP TERTILES. Table 3 shows the
clinical and biochemical parameters in patients
stratiﬁed into tertiles of baseline hs-CRP levels. Pa-
tients in the highest hs-CRP tertile were generally
older, more apt to have diabetes, and had lower
ejection fraction and estimated creatinine clearance.
These higher hs-CRP values on admission signal
higher risk of CI-AKI and adverse clinical events.
Baseline hs-CRP values were slightly but signiﬁ-
cantly correlated with various parameters that reﬂect
comorbidities and presentation acuity (Table 3).
Overall, there was a progressive increase in CI-AKI
rates from the lowest to the highest hs-CRP tertile (p
for trend ¼ 0.0001) (Figure 1A). Patients in the control
group presented an impressive increase in CI-AKI
occurrence from the ﬁrst to the third hs-CRP tertile
(p for trend <0.0001) (Figure 1B). The tertiles of
statin-treated patients, instead, do not evidence sig-
niﬁcant differences in trend (p ¼ 0.65).
After adjustment for hs-CRP (categorical variable)
and other confounders, the relationship between
statin treatment and CI-AKI development remained
markedly signiﬁcant only in the third tertile (ORadj:
FIGURE 3 Baseline hs-CRP Tertiles and Risk of CI-AKI for Pre-Speciﬁed Risk Categories
The association between statin treatment and CI-AKI occurrence in patients stratiﬁed into tertiles of baseline hs-CRP levels: on the left, patients
in the ﬁrst and second hs-CRP tertiles and on the right, the third hs-CRP tertile. Odds ratios are adjusted for sex, age, diabetes, hypertension,
low-density lipoprotein cholesterol level, creatinine (Cr) clearance at baseline, left ventricle ejection fraction (EF), contrast volume, CI-AKI risk
score, and baseline hs-CRP (categorical variable). PCI ¼ percutaneous coronary intervention; other abbreviations as in Figures 1 and 2.
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14260.20, 95% CI: 0.07 to 0.54; p ¼ 0.002) (Figure 2).
Moreover, statin treatment showed the greatest effect
in the third baseline hs-CRP tertile for all the pre-
speciﬁed risk categories of patients (Figure 3).
EFFECT OF STATIN PRE-TREATMENT ON CLINICAL
OUTCOME BY BASELINE HS-CRP TERTILES. The
incidence of cumulative adverse cardiovascular and
renal events at 30 days was markedly higher in pa-
tients in the third tertile (p for trend <0.0001)
(Figure 4A). Compared with control subjects, statin-
treated patients in the third tertile presented a
signiﬁcantly lower rate of such events (7.2% vs.
17.4%, p ¼ 0.043) (Figure 4B). Follow-up at 6 months
showed continued higher rates of adverse events in
patients with higher baseline hs-CRP (third tertile)
(Figure 5A) but with a positive trend toward lower
rates of death or myocardial infarction in statin-
treated patients (6.02% vs. 13.04%, p ¼ 0.12)
(Figure 5B).DISCUSSION
The present analysis of the PRATO-ACS data, in
particular CRP levels, shows a close relationship be-
tween baseline hs-CRP levels and CI-AKI occurrence
in patients with ACS subjected to early invasive
strategy. The magnitude of CI-AKI reduction attrib-
utable to rosuvastatin pre-treatment was substan-
tially greater in patients with higher baseline hs-CRP
than in patients with lower levels. The clinical bene-
ﬁts are evidenced by lower rates of adverse cardio-
vascular and renal events that are especially notable
in patients with higher baseline hs-CRP levels.
In the last few decades, research has demonstrated
the important role of inﬂammation in ACS; it not
only promotes the development of atheroma, but
also contributes decisively to precipitating sub-
sequent acute thrombotic complications (3). More-
over, elevated circulating markers of inﬂammation, in
particular CRP, predict an unfavorable clinical course,
FIGURE 4 Cumulative Adverse Clinical Events at 30 Days by Baseline hs-CRP Tertiles
Adverse cardiovascular and renal events (acute renal failure requiring dialysis, persistent
renal damage, all-cause mortality, myocardial infarction, or stroke) at 30 days by baseline
high-sensitivity C-reactive protein (hs-CRP) tertiles: (A) overall population (504 patients);
(B) patients divided into statin and control groups.
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1427independent of the severity of atherosclerosis (1) or the
levels of traditional risk factors (17,18).
Systemic inﬂammation is also associated with
impaired renal function (7); it can predict worsening
of renal function in both patients with manifest
chronic kidney disease (7) and patients with subclin-
ical renal disease (19). In this very vulnerable popu-
lation, CRP is a relevant prognostic indicator of
adverse cardiovascular events (20).
CI-AKI is a multifactorial process but, in particular,
various inﬂammation-related factors, including
endothelial dysfunction, oxidative stress, and renal
vasoconstriction, can actively inﬂuence its develop-
ment (9,21). Moreover, systemic inﬂammation could
render the kidneys more vulnerable to local inﬂam-
matory processes elicited by iodinated contrast
medium reabsorption following angiographic pro-
cedures, favoring development of CI-AKI (8–10).
Recent clinical studies indicate that there is a
signiﬁcant independent association between pre-
procedural CRP levels and CI-AKI occurrence in both
stable coronary artery disease patients submitted to
elective percutaneous coronary intervention (PCI)
(22) and ST-segment elevation myocardial infarction
patients submitted to primary PCI (23). We note that
these studies showed a signiﬁcant association be-
tween pre-procedural CRP and clinical outcome
notwithstanding the different clinical settings.
The present analysis of the PRATO-ACS study
conﬁrms the relationship between baseline hs-CRP
levels and CI-AKI development even in NSTE-ACS
patients subjected to early invasive strategy and
shows a close link between baseline hs-CRP levels
and prognosis. The present study shows that baseline
hs-CRP (correlated with pre-existing comorbidities,
extent of myocardial damage, and other inﬂamma-
tory markers) helps identify patients with particularly
high clinical risk–those very patients who presented
phenotypes associated with higher risk of CI-AKI
development.
EFFECT OF STATIN PRE-TREATMENT. In stable cor-
onary artery disease and ACS patients, the reduc-
tion of risk for cardiovascular events attributable
to statin therapy is substantially greater among
patients with high levels of inﬂammation (6,24,25).
A number of randomized clinical trials and re-
gistry settings have indicated that the apparent
cardiovascular and renoprotective effects of statin
treatment are probably mediated by its anti-
inﬂammatory properties (6,19). In fact, the anti-
inﬂammatory action of statins is well documented
both in vitro (26) and in vivo (27). In patients with
ACS, statin administration led to signiﬁcantly lower
CRP levels after PCI (11,12,28) and lower CRP levelsat follow-up resulting in evidently better clinical
outcome (29).
The beneﬁcial effects against CI-AKI occurrence
exerted by statin pre-treatment (loading) in statin-
naïve patients with ACS (11,12,14,15) could well
be related to the acute non-lipid-mediated pro-
perties of statins, including their anti-inﬂammatory
mechanisms. The results of the present in-depth
analysis show an incrementally beneﬁcial effect of
statin pre-treatment in patients with very high
baseline CRP levels, thus further supporting this
hypothesis.
Even short-term statin treatment may reduce sus-
ceptibility to CI-AKI given its anti-inﬂammatory ef-
fects, both systemic and on the kidneys in particular.
In fact, statin treatment increases tubular proteinuria
in a dose-dependent manner, potentially leading to
lower levels of peri-tubular inﬂammation (30,31). The
FIGURE 5 Cumulative Adverse Clinical Events at 6 Months by Baseline hs-CRP Tertiles
Adverse cardiovascular events (death or myocardial infarction [MI]) at 6 months by
baseline high-sensitivity C-reactive protein (hs-CRP) tertiles: (A) overall population
(504 patients); (B) patients divided into statin and control groups.
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1428diminished levels of inﬂammation render the tubular
cells less vulnerable to the direct toxic effects of
contrast medium.
In the PRATO-ACS study, high-dose rosuvastatin
treatment administered on admission was associated
with a signiﬁcantly lower rate of 30-day adverse car-
diovascular and renal events and a continued positivetrend at 6 months. The present study also shows that
those patients with higher markers of inﬂammation
are more subject to adverse events, and it is these
very patients who beneﬁt most from statin pre-
treatment.
Patients with NSTE-ACS are a particularly high-
risk group: they require aggressive medical man-
agement, including early high-dose statin therapy.
Statin beneﬁts are evident independent of baseline
hs-CRP in all risk categories, but this study shows
that the higher the baseline hs-CRP levels, the higher
the CI-AKI and adverse event rates, and the higher
the beneﬁts of on-admission statin administration.
Whether or not these beneﬁts are due to the anti-
inﬂammatory properties of rosuvastatin cannot be
established on the basis of this study, but our ﬁnd-
ings represent a further reason in favor of early use
of high-dose statin therapy and assessment of
hs-CRP in ACS patients.
STUDY LIMITATIONS. hs-CRP was measured only on
admission. We did not repeat this measurement, and
therefore, we do not know whether hs-CRP levels
were lowered by the statin before contrast medium
administration or subsequently.CONCLUSIONS
High-dose rosuvastatin therapy administered on
admission reduced CI-AKI occurrence and improved
short- and mid-term clinical outcome in statin-naïve
patients with NSTE-ACS, who were subjected to early
invasive strategy with particularly remarkable effects
in patients with higher baseline hs-CRP levels.
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